Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK

Current Medical Research and Opinion

Volumn 21, Issue 10, 2005, Pages 1505-1517

  Remák, Edit ^a   Brown, R E ^a   Yuen, C ^b   Robinson, A ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Janssen Cilag   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

Author keywords

Cost effectiveness; Cost utility analysis; GORD; Markov model; PPI; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; PROTON PUMP; SULFOXIDE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG CAPSULE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; QUALITY OF LIFE; TABLET; UNITED KINGDOM; DRUG ANTAGONISM;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; GASTROESOPHAGEAL REFLUX; GREAT BRITAIN; HUMANS; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES;

EID: 27144498626     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X65330     Document Type: Article

References (42)

1. Dent J, Jones R, Kahrilas P, et al. Management of gastro-oesophageal reflux disease in general practice. BMJ 2001;322:344-7
2. Dent J, Brun H, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval workshop report. Gut 1999;44:S1-16
3. Goeree R, O'Brien B, Hunt R, et al. Economic evaluation of long term management strategies for erosive oesophagitis. Pharmacoeconomics 1999;16:679-97
4. National Institute for Clinical Excellence - National Guideline Research and Development Unit. Dyspepsia: managing adult patients in primary care FINAL CONSULTATION DRAFT 18/02/2004. Available from http://www.nice.org.uk/ [Accessed 5 March 2004]
5. Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: A cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med 1997; 102:78-88
6. Dean BB, Siddique RM, Yamashita BD, et al. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis. Am J Health Syst Pharm 2001;58:1338-46
7. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 1997;92:2179-87
8. Wahlquist P, Junghard O, Higgins A, et al. Cost-effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK. Pharmacoeconomics 2002;20:279-87
9. Stålhammar N-O, Carlsson J, Peacock R, et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Pharmacoeconomics 1999;16:483-97
10. Wahlquist P, Junghard O, Higgins A, et al. Cost-effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis. Pharmacoeconomics 2002;20:267-77
11. McGuire A. Theoretical concepts in the economic evaluation of health care. In: Drummond M, McGuire A, editors. Economic evaluation in health care - Merging theory with practice. Oxford University Press, 2001, pp. 1-21
12. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73
13. Holtmann G, Bytzer P, Metz M, et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:479-85
14. Dekkers CP, Beker JA, Thjodleifsson B, et al. Double-blind comparison (correction of double-blind, placebo-controlled comparison) of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Alimentary Pharmacol Therapeutics 1999;13:49-57
15. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996;91:1749-57
16. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65
17. Armstrong D, Pare P, Pericak D, et al. and the Canadian Pantoprazole GERD Study Group. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001;96:2849-57
18. Robinson M, Fitzgerald S, Hegedus R, et al. and FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002;16:445-54
19. Kartman B. Utility and willingness to pay measurements among patients with gastroesophageal reflux disease. Am J Gastroenterol 2001;98:S38-43
20. Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49:451-3
21. Cooper AL, Baxter G. Efficacy of lansoprazole on demand therapy in the treatment of non-erosive reflux disease and functional ulcer-like dyspepsia. Gut 2003;52:A137
22. Kaspari S, Kupcinkas L, Fischer R, et al. Effective long-term management of patients suffering from mild GERD with on-demand therapy with pantoprazole 20 mg. Gut 2003;52:A126
23. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-9
24. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care - Merging theory with practice. Oxford University Press, 2001, pp.172-214
25. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics 2001;10:779-87
26. Miner Jr P, Orr W, Filippone J, et al. Rabeprazole in non-erosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002;97:1332-9
27. Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003;18:875-82
28. Vicari F, Belin J, Marek L. Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux oesophagitis: results of a French multicentric double blind trial. Gastroenterol 1998;114:A324
29. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83
30. Thjodleifsson B, Beker JA, Dekkers C, et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. Dig Dis Sci 2000;45:845-53
31. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27-34
32. Robinson M, Lanza F, Avner D, et al. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:859-67
33. Plein K, Hotz J, Wurzer H, et al. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000;12:425-32
34. Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut 1995;36:492-8
35. Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux esophagitis: Metropole Study Results. Aliment Pharmacol Ther 2003;17: 333-41
36. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo controlled randomised trial. Aliment Pharmacol Ther 1999;13:907-14
37. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002;14: 857-63
38. Bytzer P, Blum AL, De Herdt D, et al. The Trial Investigators. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004;20:181-8
39. Market data (2003)
40. British National Formulary 46, 2003. British Medical Association - Royal Pharmaceutical Society of Great Britain
41. Personal and Social Services Research Unit. Unit costs of health and social care 2003. Netten A, Curtis L, editors. University of Kent at Canterbury
42. NHS Reference Costs 2003. Available from http://www.doh. gov.uk/nhsexec/refcosts [Accessed 11 March 2004]